Got a couple of requests from my YouTube community, so i decided to walk through LASACO H1 2025 numbers.

As always. Nothing said is investment or trading advice.

Nu Bank Is a Latin American focused fintech. In this episode, i walk through its Q1 2025 numbers and share my thoughts on an ideal entry price.

As always this is not investment or trading advice.

Here's a brief run through Crowdstrike Q2 2026 numbers. Crowdstrike is a cyber security stock.

In this epsiode, i walk through the numbers and opine on what imo would be an intial entry point.

As always, this is not financial or trading advice.

In this episode, i zero in on transpower following large off market trades in fhe last few trading sessions. I also do some napkin math if it gets paid a decent chunk of the debt its owed by the Federal Government. As always, this is not trading or investment advice.

Here is a recording of the greentickertale twitter space with Mr Reuben Ossai the MD/CEO of The Initiates Plc (TIP).

TIP is a waste management firm listed on the NGX (Nigerian stock market).

Mr Ossai walks us through the company's history as well as mid to long term plans,

In this episode, i walk through H1 2025 results for Prestige Assurance. H1 2025 means the first 6 months of 2025 for the company.

As always, please note that content is not investment or trading advice.

May and Baker is one of the smaller players of the pharma players listed on the NGX.

Here's my walk through its H1 2025 results.

Neimeth is the smallest of the big 4 pharma firms listed on the NGX. Here are my views on its H1 2025 earnings and the company's share price.

Mecure is one of the 5 listed players in the pharma space on the NGX.

In fhis episode i discuss its H1 2025 earnings: Revenue split and pain points.

Here's my first of 3 episodes on pharma firms H1 2025 earnings on the NGX.

I walk through Fidson H1 2025 earnings as well as my near and mid term price targets.

As always, please note that this is not investment or trading advice.